 Home > Active Ingredient News > Endocrine System > Diabetes Care: Dulaglutide significantly improves liver metabolism in patients with obesity and type 2 diabetes

Diabetes Care: Dulaglutide significantly improves liver metabolism in patients with obesity and type 2 diabetes

 Last Update: 2021-07-31
 Source: Internet
 Author: User

Tags

zovia 1 35

all solution

hydrochlorothiazide 25 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

GLP-1 RA is not insulin, but a new type of insulin secretagogue.

Trulicity ( dulaglutide ) is a glucagon-like peptide -1 ( GLP-1 ) receptor agonist ( RA ), injected once a week, combined with diet control and exercise, for 2 type diabetes ( diabetes mellitus T2DM ) to improve glycemic control in adult patients

2020 Nian 09 Yue 03 RiLilly ( Eli Lilly ) announced that the US Food and Drug Administration Bureau ( the FDA ) has approved the pull of the glycopeptide 2 additional doses ( 3.

2020 Nian 09 Yue 03 Ri Lilly ( Eli Lilly ) announced that the US Food and Drug Administration Authority ( managing the FDA the FDA ) has approved the pull of the glycopeptide 2 additional doses ( 3.

Currently, dulaglycotide is being developed for non-alcoholic steatohepatitis ( NAH ) and chronic kidney disease

In this 2b of the study, 834 name BMI≥25 kg / m2 and metformin inadequate control T2DM adults ( HbAIc of 7.

In this 2b of the study, 834 name BMI≥25 kg / m2 and metformin inadequate control of metformin T2DM adults ( HbAIc of 7.

Dulaglutide (double-blind) and liraglutide (open-label) are given by subcutaneous injection once a day

The results showed that, compared with placebo, the degree of pull glycopeptide compared with placebo, the degree of pull glycopeptide compared with placebo, the degree of pull glycopeptide At 14 weeks and 54 weeks significantly reduced HbA1c and Body weight (all P<0.

Changes in blood glucose and weight results from baseline to week 54 between different groups

Dulaglutide treatment for 54 weeks improved blood sugar control and weight loss in overweight/obese and type 2 diabetes patients

references:

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study .

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study .
Diabetes Care 2021 Jun; 44(6): 1433-1442.
https://doi.
org/ 10.
2337 / dc20-2151 Effects of Metabolic Cotadutide oN and the Parameters in Hepatic or Obesity and Overweight Adults With the Type 2 Diabetes: A-54 is Week Randomized Phase 2B Study

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.